Blindness and paralysis can be devastating consequences of the little-known disease Myelin oligodendrocyte glycoprotein antibody disorders (MOGAD). But an Australian research collaboration is looking to change this after gaining a better understanding of how the condition behaves, especially in cases of vision loss.
Often referred to as “a cousin of multiple sclerosis (MS)” due to shared symptoms, MOGAD is an autoimmune condition where the body attacks a protein in the brain, resulting in a swollen central nervous system. The disease affects adults and children but is much less common, and less understood than MS.
According to the University of Sydney, a major challenge with the condition is that some people will experience only one attack in their lifetime while around 40% have recurring attacks, each leading to additional impairment and disability. Strong immunosuppressants can help prevent relapses but drug side effects mean it is vital to identify which patients need this ongoing treatment.
More than 50 Australian scientists, headed by Professor Fabienne Brilot from the University of Sydney and the Kids Neuroscience Centre at Sydney Children’s Hospitals Network, have been able to achieve this.
“The disease is so new, and so newly described that there is a lot we still don’t know. But whether or not patients will relapse is the number one question asked of neurologists. One we can now potentially answer,” she said.
In a new study published in the Journal of Neurology, Neurosurgery & Psychiatry, the researchers detail the discovery of a way to predict which adult patients will experience a relapsing course by examining where the antibody binds on the MOG protein (the epitope) in patients who have tested positive for the MOG antibody.
They found in around 25% of patients the antibody was not binding at the dominant epitope (called non-p42 epitope) and these were the patients experiencing a relapse.
They also found this was most common in patients who at the initial onset of the disease were affected by vision impairment (lesions on the optic nerve) as opposed to those experiencing issues with movement (lesions on the spinal cord).
Prof Brilot said the clinical translation of the finding is significant given this is the first and only test available.
“The prediction of a relapsing course in MOGAD means neurologists can make more informed treatment decisions. They can initiate maintenance immunosuppression early rather than waiting for relapse to occur, as has happened with multiple sclerosis,” she said.
“It will help prioritise patients in busy neuroimmunology clinics and will also help recruitment into clinical trials which are vital to undercover the best treatments for this disease.”
The discovery builds on Prof Brilot’s previous work, including as a key member of the global consortium that published the first consensus on diagnostic criteria for MOGAD in 2023.
The disease is diagnosed by the detection of the MOG autoantibody. Her lab at Westmead has been the Australia-wide testing point for the antibody for the last 10 years, testing serum or blood of 4,000 Australian patients a year.
Based on her experience overseeing MOGAD antibody testing, Prof Brilot aims to have testing for early identification of those at risk relapse available for clinical purposes in adults soon. Simultaneously, her team is carrying out the same research with children with MOGAD, hoping the discovery could also help young people impacted by the disease.
More reading
Dr Neil Miller’s neuro-ophthalmology update at RANZCO 2023
New treatment for Visual Snow Syndrome
Neuro-ophthalmology: what the eyes tell us about the brain
